

Ontario Public Drug Programs

Drug Submission Status
Updated: April 19, 2013

Complete Streamlined Multiple-Source Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Apotex Inc.	Apo-Eletriptan	Relpax	eletriptan hydrobromide	20mg	tablet	02386054
Apotex Inc.	Apo-Eletriptan	Relpax	eletriptan hydrobromide	40mg	tablet	02386062
Sterimax Inc.	Pilocarpine Hydrochloride Tablets, USP	Salagen	pilocarpine hydrochloride	5mg	tablet	02402483
Teva Canada Limited	Teva-Nabilone	Cesamet	nabilone	0.25mg	capsule	02392925

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Teva Canada Limited	Novo-Glimepiride	Amaryl	glimepiride	2mg	tablet	02273764
Teva Canada Limited	Novo-Glimepiride	Amaryl	glimepiride	4mg	tablet	02273772